{"prompt": "['2014-0546', 'August 7, 2017', 'Page 27 of 49', 'Table 3', 'Oral Rigosertib Step-by-step Dose Reductions for Urinary Toxicity', 'Episodes of', 'Starting Dose', 'Dose Adjustment', 'Urinary Toxicity', 'Morning', 'Afternoon', 'Morning', 'Afternoon', '1', '560 mg', '560 mg', '560 mg', '280 mg', '2', '560 mg', '280 mg', '420 mg', '280 mg', '3', '420 mg', '280 mg', '420 mg', '210 mg', '4', '420 mg', '210 mg', '280 mg', '210 mg', '5', '280 mg', '210 mg', '280 mg', '140 mg', '6', '280 mg', '140 mg', '140 mg', '140 mg', '7', '140 mg', '140 mg', '140 mg', '70 mg', '8', '140 mg', '70 mg', '70 mg', '70 mg', '9', '70 mg', '70 mg', '140 mg every other day', '0 mg', 'Should a further episode of urinary toxicity occur, the patient will be withdrawn from the trial and', 'followed.', '3.5.4.2.2. Treatment-related >Grade 3 Toxicity other than Urinary Symptoms', 'If any treatment-related non-hematologic toxicity of Grade 3 or higher is present on the day of', 'administration of rigosertib:', '1. Rigosertib treatment will be withheld until resolution to Grade 1 or Baseline toxicity', 'grading, whichever is greater, then dosing will be resumed at full dose;', '2. If the same treatment-related toxicity of Grade 2 or higher reoccurs, rigosertib dosing will', 'be reduced (see Table 2) at the next administration;', '3.', 'If the same treatment-related non-hematologic toxicity of > Grade 2 reoccurs, rigosertib', 'dose will be reduced further (see Table 2) after resolution to Grade 1 or Baseline status;', '4. If the same toxicity persists and is not tolerable, the patient will be withdrawn from the', 'study.', '3.5.5. Treatment Compliance', \"Each dose of rigosertib should be administered on the day dictated by the patient's dosing schedule.\", 'Patients should not take missed doses. Patients will be given a diary to document compliance with', 'study drug.']['2014-0546', 'August 7, 2017', 'Page 28 of 49', '3.5.6.', 'Management of Urinary Symptoms', 'Good hydration (ie, at least 2 liters of water per day) is recommended for all patients. If dysuria', 'develops, the following therapies may be prescribed:', 'Sodium bicarbonate tablets if the patient is not on a sodium-restricted diet: 650 mg tablets', 'given BID with two 8-ounce glasses of water 1 hr after rigosertib administration;', 'Pyridium if the patient has a normal creatinine value and is not allergic to phenazopyridine:', '100 mg 3 times daily orally, taken with a full glass of water and food; pyridium should not', 'be taken for more than 2 days.', 'Please refer to Section 3.5.4.2.1 for dosing adjustments in case of > Grade 2 urinary toxicity.', '3.5.7.', 'Concomitant Therapy', 'All concomitant medications (including non-prescription drugs and herbal therapies) received', \"from 30 days prior to study entry until the end of study will be recorded in the patient's chart. The\", 'information should include the name of the drug, indication, daily dose with units, and the start', 'and stop date(s) of administration.', 'All patients may be transfused when judged to be medically necessary by the Investigator. The', 'date and type of transfusion, the Hgb and/or PLT values prior to transfusion (obtained at the time', 'of type/cross match), and the number of units transfused must be recorded on the eCRF. The reason', 'for transfusion should also be documented.', 'Recombinant G-CSF or granulocyte-monocyte colony stimulating factor (GM-CSF) can be used', 'as clinically indicated (e.g., for Grade 3 or 4 neutropenia with recurrent or resistant bacterial', 'infections). Recommended dosage for G-CSF is 5 g/kg subcutaneous (SC) daily (NCCN 2011).', 'Based on findings from nonclinical studies, rigosertib inhibits CYP isoforms 2C9 and 2C8 in vitro', 'at clinically relevant concentrations. Caution should be exercised and dose reduction of the', 'concomitant substrate drugs should be considered when dosing rigosertib concurrently with', 'medications with narrow therapeutic range that are substrates of CYP2C9 or CYP2C8 (see', 'Appendix 8). In addition, rigosertib was found to be a P-gp substrate, but not a P-gp inhibitor (see', 'list of potential P-gp inhibitors in Appendix 9).', '3.6.', 'Statistical Methods', 'This study is a Phase II, proof-of-concept, single-arm study of the efficacy and safety of oral', 'rigosertib in patients with MF and anemia.', '3.6.1.', 'Sample Size Considerations', 'The primary endpoint will be the proportion of patients achieving spleen response by Week 24 or', 'Week 48 (defined as > 35% spleen volume reduction from Baseline, which requires confirmation']\n\n###\n\n", "completion": "END"}